Alleviant ALLAY-HFrEF Study

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 350 participants.

Also called NCT06812533

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 350 participants (planned count) (from the registry)
Sponsor
Alleviant Medical, Inc. (from the registry)
Registry
  • NCT NCT06812533
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Australia, Belgium, Canada, Georgia, Greece, Israel, New Zealand, Poland, Serbia, Spain (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06812533. Randomized; double masking; primary purpose treatment. Start 2025-03-10 (actual); primary completion 2028-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Alleviant ALLAY-HFrEF Study
Condition
Heart Failure
Intervention (Device)
Alleviant ALV1 System
Intervention (Other)
Sham-Control
Lead sponsor
Alleviant Medical, Inc. (class: industry)

Record details

Record id
cardio:ct-nct06812533
Content hash
8afa101451c7aa8b2c460f988e45122fdb2dbee0132c2b2db3d616ebc1d4a1fd